Could a diabetes drug help heart defect patients lose weight?
NCT ID NCT07354880
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug tirzepatide (Munjaro) in 30 obese adults with congenital heart disease. Over 6 months, half get the drug and half get a placebo. Researchers will check if it improves exercise ability, heart function, and cholesterol. It is one of the first studies to look at modern weight-loss drugs in this specific group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tirzepatide (Munjaro)
- What this could lead to
- If it works, this could point toward a safe way to help people with congenital heart disease lose weight and improve heart health.
- What could go wrong
- This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The drug may cause side effects like nausea or vomiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT CONGENITAL HEART DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fiber gummies: a tasty new weapon against obesity?
- Can a diabetes drug improve joint replacement outcomes?
- Can a new pill help older adults lose weight without losing strength?
- Can one avocado a day sharpen the aging brain?
- Can a strict diet put type 2 diabetes into remission?
- Can Weight-Loss surgery alter how medications work?